Optimization and high-throughput screening of antimicrobial peptides

Current Pharmaceutical Design

Volumn 16, Issue 28, 2010, Pages 3204-3211

  Blondelle, Sylvie E ^a   Lohner, Karl ^b  

^a Division of Membrane Biology   (United States)

^b ERICH SCHMID INSTITUTE OF MATERIALS SCIENCE   (Austria)

Author keywords

Antimicrobial peptides; High throughput screening; Peptide libraries; Structure activity relationship

Indexed keywords

ASPARTYLHISTIDYLARGINYLASPARAGINYLPROLYLASPARAGINYLTYROSYLSERYLTRYPTOPHYLLEUCYLLYSYLSERINE; BACTENECIN; BACTERIAL ENZYME; CECROPIN A; CHEA KINASE; CYSTEINYLGLUTAMINYLASPARTYLTHREONYLPROLYLTYROSYLARGINYLASPARAGINYLCYSTEINE; DAPTOMYCIN; DEXTRO AMINO ACID; FUNGAL ENZYME; GRAMICIDIN S; ISEGANAN; METHIONYLHISTIDYLARGINYLTRYPTOPHYLLYSYLLEUCYLPHENYLALANYLTHREONYLLYSYLLEUCYLGLYCYLALANYLVALYLLEUCYLLYSINE; NISIN; OMIGANAN; PEPTIDE LIBRARY; PEXIGANAN; PLECTASIN; POLYMYXIN B; POLYPEPTIDE ANTIBIOTIC AGENT; PROTEGRIN; PROTEIN KINASE C; SYNTHETIC PEPTIDE; THREONYLMETHIONYLGLYCYLPHENYLALANYLTHREONYLALANYLPROLYLARGINYLPHENYLALANYLPROLYLHISTIDYLTYROSINE; UNCLASSIFIED DRUG;

ALGORITHM; AMINO ACID SEQUENCE; ANTIBACTERIAL ACTIVITY; ANTIMICROBIAL ACTIVITY; BACILLUS SUBTILIS; BACTERIAL GROWTH; BACTERICIDAL ACTIVITY; BACTERIOSTASIS; BINDING AFFINITY; BIOLOGICAL ACTIVITY; BREVIBACILLUS BREVIS; CHROMOSOME SEGREGATION; CLINICAL TRIAL; COMBINATORIAL CHEMISTRY; COMPUTER MODEL; DNA LIBRARY; DNA STRAND BREAKAGE; DRUG POTENCY; ESCHERICHIA COLI; GRAM NEGATIVE BACTERIUM; GROWTH INHIBITION; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN GENOME PROJECT; INNATE IMMUNITY; LISTERIA MONOCYTOGENES; MEMBRANE BINDING; NONHUMAN; PEPTIDE SYNTHESIS; PHAGE DISPLAY; PNEUMOCOCCAL INFECTION; PRIORITY JOURNAL; PROCESS OPTIMIZATION; PROTEIN DEGRADATION; PSEUDOMONAS AERUGINOSA; QUANTITATIVE ANALYSIS; QUANTITATIVE STRUCTURE ACTIVITY RELATION; REVIEW; SALMONELLA TYPHIMURIUM; SOLID PHASE SYNTHESIS; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS; THIN LAYER CHROMATOGRAPHY;

ANIMALS; ANTI-INFECTIVE AGENTS; DRUG DESIGN; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; PEPTIDE LIBRARY; PEPTIDES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 78649813603     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161210793292438     Document Type: Review

References (107)

1. Mayr LM, Bojanic D. Novel trends in high-throughput screening. Curr Opin Pharmacol 2009; 9: 580-8.
2. Wang G, Li X, Wang Z. APD2: the updated antimicrobial peptide database and its application in peptide design. Nucleic Acids Res 2009; 37: D933-7.
3. Joanne P, Nicolas P, El Amri C. Antimicrobial peptides and viral fusion peptides: how different they are? Protein Pept Lett 2009; 16: 743-50.
4. Lohner K, Blondelle SE. Molecular mechanisms of membrane perturbation by antimicrobial peptides and the use of biophysical studies in the design of novel peptide antibiotics. Comb Chem High Throughput Scr 2005; 8: 241-56.
5. Hale JD, Hancock RE. Alternative mechanisms of action of cationic antimicrobial peptides on bacteria. Expert Rev Anti Infect Ther 2007; 5: 951-9.
6. Boman HG. Antibacterial peptides: Basic facts and emerging concepts. J Intern Med 2003; 254: 197-215.
7. Maloy WL, Kari UP. Structure-activity studies on magainins and other host defense peptides. Biopolymers 1995; 37: 105-22.
8. Melo MN, Dugourd D, Castanho MA. Omiganan pentahydrochloride in the front line of clinical applications of antimicrobial peptides. Recent Pat Anti-infect Drug Discov 2006; 1: 201-7.
9. Kollef M, Pittet D, Sánchez García M, et al. Prevention of Pneumonia Study (POPS-1) Trial Group. A randomized double-blind trial of iseganan in prevention of ventilator associated pneumonia. Am J Respir Crit Care Med 2006; 173: 91-7.
10. Edwards PJ, Morwood K. Pharmaceutical compositions against gastric disorders containing bacteriocins. PCT Int. Appl. WO 92 18,143 (Cl. A61K37/02), 29 Oct 1992, GB Appl. 91/8,129, 15 Apr 1991; 15 pp. (CA).
11. Cruz DN, Perazella MA, Bellomo R, et al. Effectiveness of polymyxin B-immobilized fiber column in sepsis: a systematic review. Crit Care 2007; 11: R47.
12. Gause GF, Brazhnikova MG. Gramicidin S and its use in the treatment of infected wounds. Nature 1944; 154: 703.
13. Gause GF, Brazhnikova MG. Gramicidin S. Origin and mode of action. Lancet 1944; 247: 715-6.
14. Velden WJ, van Iersel TM, Blijlevens NM, Donnelly JP. Safety and tolerability of the antimicrobial peptide human lactoferrin 1-11 (hLF1-11). BMC Med 2009; 7: 44-51.
15. Hamill P, Brown K, Jenssen H, Hancock RE. Novel anti-infectives: is host defence the answer? Curr Opin Biotechnol 2008; 19: 628-36.
16. Schots R, Kaufman L, Van Riet I, et al. Proinflammatory cytokines and their role in the development of major transplant-related com plications in the early phase after allogeneic bone marrow transplantation. Leukemia 2003; 17: 1150-6.
17. Vaara M. New approaches in peptide antibiotics. Curr Opin Pharmacol 2009; 9: 571-6.
18. Houghten RA. General method for the rapid solid-phase synthesis of large numbers of peptides: specificity of antigen antibody interaction at the level of individual amino acids. Proc Natl Acad Sci USA 1984; 82: 5131-5.
19. Geysen HM, Meloen RH, Barteling SJ. Use of peptide synthesis to probe viral antigens for epitopes to a resolution of a single amino acid. Proc Natl Acad Sci USA 1984; 81: 3998-4002.
20. Shin DS, Kim DH, Chung WJ, Lee YS. Combinatorial solid phase peptide synthesis and bioassays. J Biochem Mol Biol 2005; 5: 517-25.
21. Houghten RA, Pinilla C, Blondelle SE, Appel JR, Dooley CT, Cuervo JH. Generation and use of synthetic peptide combinatorial libraries for basic research and drug discovery. Nature 1991; 354: 84-6.
22. Blondelle SE, Lohner K. Combinatorial libraries: a tool to design antimicrobial and antifungal peptide analogues having lytic specificities for structure-activity relationship studies. Biopolymers 2000; 55: 74-87.
23. Blondelle SE, Pinilla C, Boggiano C. Synthetic combinatorial libraries as an alternative strategy for the development of novel treatments for infectious diseases. Methods Enzymol 2003; 369: 322-44.
24. Jenssen H, Hamill P, Hancock REW. Peptide antimicrobial agents. Clin Microbiol Rev 2006; 19: 491-511.
25. Yeaman MR, Yount NY. Mechanisms of antimicrobial peptide action and resistance. Pharmacol Rev 2003; 55: 27-55.
26. Roychoudhury S, Blondelle SE, Collins SM, et al. Use of combinatorial library screening to identify inhibitors of a bacterial twocomponent signal transduction kinase. Mol Divers 1998; 4: 173-82.
27. Cassell G, Klemm M, Pinilla C, Segall A. Dissection of bacteriophage lambda site-specific recombination using synthetic peptide combinatorial libraries. J Mol Biol 2000; 299: 1193-202.
28. Gunderson CW, Boldt JL, Authement RN, Segall AM. Peptide wrwycr inhibits the excision of several prophages and traps holliday junctions inside bacteria. J Bacteriol 2009; 191: 2169-76.
29. Gunderson CW, Segall AM. DNA repair, a novel antibacterial target: Holliday junction-trapping peptides induce DNA damage and chromosome segregation defects. Mol Microbiol 2006; 59: 1129-48.
30. Cherkasov A, Hilpert K, Jenssen H, et al. Use of artificial intelligence in the design of small peptide antibiotics effective against a broad spectrum of highly antibiotic-resistant superbugs. ACS Chem Biol 2009; 4: 65-74.
31. Appelt C, Wessolowski A, Dathe M, Schmieder P. Structures of cyclic, antimicrobial peptides in a membrane-mimicking environment define requirements for activity. J Pept Sci 2008; 14: 524-7.
32. Zelezetsky I, Tossi A. Alpha-helical antimicrobial peptides using a template to guide structure-activity relationship studies. Biochim Biophys Acta 2006; 1758: 1436-49.
33. Blondelle SE, Houghten RA. Design of model amphipathic peptides having potent antimicrobial activities. Biochemistry 1992; 31: 12688-94.
34. Blondelle SE, Takahashi E, Houghten RA, Pérez-Payá E. Rapid identification of compounds with enhanced antimicrobial activity by using conformationally defined combinatorial libraries. Biochem J 1996; 313: 141-7.
35. Rathinakumar R, Walkenhorst WF, Wimley WC. Broad-spectrum antimicrobial peptides by rational combinatorial design and highthroughput screening: The importance of interfacial activity. J Amer Chem Soc 2009; 131: 7609-17.
36. Wipf P. Synthetic studies of biologically active marine cyclopeptides. Chem Rev 1995; 95: 2115-34.
37. Hamada Y, Shioiri T. Recent progress of the synthetic studies of biologically active marine cyclic peptides and depsipeptides. Chem Rev 2005; 105: 4441-82.
38. Pomilio AB, Battista ME, Vitale AA. Naturally-occurring cyclopeptides: Structures and bioactivity. Curr Org Chem 2006; 10: 2075-121.
39. Sandhu P, Xu X, Bondiskey PJ, et al. Disposition of caspofungin, a novel antifungal agent, in mice, rats, rabbits, and monkeys. Antimicrob Agents Chemother 2004; 48: 1272-80.
40. Xiao Q, Pei D. High-throughput synthesis and screening of cyclic peptide antibiotics. J Med Chem 2007; 50: 3132-7.
41. Frank R. Spot synthesis: an easy technique for positionally addressable, parallel chemical synthesis on membrane support. Tetrahedron 1992; 48: 9217-32.
42. Weiser AA, Or-Guil M, Tapia V, et al. SPOT synthesis: reliability of array-based measurement of peptide binding affinity. Anal Biochem 2005; 342: 300-11.
43. Hilpert K, Volkmer-Engert R, Walter T, Hancock RE. Highthroughput generation of small antibacterial peptides with improved activity. Nat Biotechnol 2005; 23: 1008-12.
44. Sidhu SS. Phage display in pharmaceutical biotechnology. Curr Opin Biotechnol 2000; 11: 610-6.
45. Christensen DJ, Gottlin EB, Benson RE, Hamilton PT. Phage display for target-based antibacterial drug discovery. Drug Discov Today 2001; 6: 721-7.
46. Pini A, Giuliani A, Falciani C, et al. Antimicrobial activity of novel dendrimeric peptides obtained by phage display selection and rational modification. Antimicrob Agents Chemother 2005; 49: 2665-72.
47. El Zoeiby A, Sanschagrin F, Darveau A, Brisson JR, Levesque RC. Identification of novel inhibitors of Pseudomonas aeruginosa MurC enzyme derived from phage-displayed peptide libraries. J Antimicrob Chemother 2003; 51: 531-43.
48. Paradis-Bleau C, Lloyd A, Sanschagrin F, et al. Phage displayderived inhibitor of the essential cell wall biosynthesis enzyme MurF. BMC Biochem 2008; 9: 33-43.
49. Morales Betanzos C, Gonzalez-Moa MJ, Boltz KW, vander Werf BD, Johnston SA, Svarovsky SA. Bacterial glycoprofiling by using random sequence peptide microarrays. ChemBioChem 2009; 10: 877-88.
50. Rosenfeld Y, Sahl HG, Shai Y. Parameters involved in antimicrobial and endotoxin detoxification activities of antimicrobial peptides. Biochemistry 2008; 47: 6468-78.
51. DeVito JA, Mills JA, Liu VG, et al. An array of target-specific screening strains for antibacterial discovery. Nat Biotechnol 2002; 20: 478-83.
52. El Zoeiby A, Beaumont M, Dubuc E, Sanschagrin F, Voyer N, Levesque RC. Combinatorial enzymatic assay for the screening of a new class of bacterial cell wall inhibitors. Bioorg Med Chem 2003; 11: 1583-92.
53. Bouhss A, Mengin-Lecreulx D, Blanot D, van Heijenoort J, Parquet C. Invariant amino acids in the Mur peptide synthetases of bacterial peptidoglycan synthesis and their modification by sitedirected mutagenesis in the UDP-MurNAc: L-alanine ligase from Escherichia coli. Biochemistry 1997; 36: 11556-63.
54. Naveh A, Potasman I, Bassan H, Ulitzur S. A new rapid and sensitive bioluminescence assay for antibiotics that inhibit protein synthesis. J Appl Bacteriol 1984; 56: 457-63.
55. Loeliger B, Caldelari I, Bizzini A, Stutzmann Meier P, Majcherczyk PA, Moreillon P. Antibiotic-dependent correlation between drug-induced killing and loss of luminescence in Streptococcus gordonii expressing luciferase. Microb Drug Resist 2003; 9: 123-31.
56. Hilpert K, Hancock RE. Use of luminescent bacteria for rapid screening and characterization of short cationic antimicrobial peptides synthesized on cellulose using peptide array technology. Nat Protoc 2007; 2: 1652-60.
57. Mygind PH, Fischer RL, Schnorr KM, et al. Plectasin is a peptide antibiotic with therapeutic potential from a saprophytic fungus. Nature 2005; 437: 975-80.
58. da Silva A Jr, Kawazoe U, Freitas FF, et al. Avian anticoccidial activity of a novel membrane-interactive peptide selected from phage display libraries. Mol Biochem Parasitol 2002; 120: 53-60.
59. Tanaka T, Kokuryu Y, Matsunaga T. Novel method for selection of antimicrobial peptides from a phage display library by use of bacterial magnetic particles. Appl Environ Microbiol 2008; 74: 7600-6.
60. Xie Q, Matsunaga S, Wen Z, et al. In vitro system for highthroughput screening of random peptide libraries for antimicrobial peptides that recognize bacterial membranes. J Pept Sci 2006; 12: 643-52.
61. Loit E, Wu K, Cheng X, Hincke MT, Altosaar I. Functional wholecolony screening method to identify antimicrobial peptides. J Microbiol Methods 2008; 75: 425-31.
62. Lohner K. New strategies for novel antibiotics: peptides targeting bacterial cell membranes. Gen Physiol Biophys 2009; 28: 105-16.
63. Bechinger B, Lohner, K. Detergent-like actions of linear amphipathic antimicrobial peptides. Biochim Biophys Acta 2006; 1758: 1529-39.
64. Lohner K, Sevcsik E, Pabst G. Liposome based biomembrane mimetic systems: Implications for lipid-peptide interactions. In: Leitmannova Liu A, Ed. Advances in planar lipid bilayers and liposomes. New York: Elsevier Inc. 2008; vol. 6: pp. 103-37.
65. Sevcsik E, Pabst G, Richter W, Danner S, Amenitsch H, Lohner K. Interaction of LL-37 with model membrane systems of different complexity - Influence of the lipid matrix. Biophys J 2008; 94: 4688-99.
66. Kolusheva S, Boyer L, Jelinek R. A colorimetric assay for rapid screening of antimicrobial peptides. Nat Biotechnol 2000; 18: 225-7.
67. Meller P, Peters R, Ringsdorf H. Microstructure and lateral diffusion in monolayers of polymerizable amphiphile. Colloid Polym Sci 1989; 267: 97-107.
68. Wenzel M, Atkinson GH. Chromatic properties of polydiacetylene films. J Amer Chem Soc 1989; 111: 6123-7.
69. 13C NMR. Macromolecules 1989; 22: 1208-15.
70. Jelinek R, Okada S, Notvez S, Charych D. Interfacial catalysis by phospholipases at conjugated lipid vesicles: colorimetric detection and NMR spectroscopy. Chem Biol 1998; 5: 619-29.
71. Jelinek R, Silbert L. Biomimetic approaches for studying membrane processes. Mol Biosyst 2009; 5: 811-8.
72. Kolusheva S, Shahal T, Jelinek R. Peptide-membrane interactions studied by a new phospholipid/polydiacetylene colorimetric vesicle assay. Biochemistry 2000; 39: 15851-9.
73. Katz M, Tsubery H, Kolusheva S, Shames A, Fridkin M, Jelinek R. Lipid binding and membrane penetration of polymyxin B nonapeptide derivatives: significance of LPS binding and effects of a hydrophobic side residue. Biochem J 2003; 375: 405-13.
74. Halevy R, Rozek A, Kolusheva S, Hancock RE, Jelinek R. Membrane binding and permeation by indolicidin analogs studied by a biomimetic lipid/polydiacetylene vesicle assay. Peptides 2003; 24: 1753-61.
75. Sheynis T, Sykora J, Benda A, Kolusheva S, Hof M, Jelinek R. Bilayer localization of membrane-active peptides studied in biomimetic vesicles by visible and fluorescence spectroscopies. Eur J Biochem 2003; 270: 4478-87.
76. Tanabe H, Qu X, Cummings J, et al. Structure-activity determinants in paneth cell alpha-defensins: Loss-of-function in mouse cryptdin-4 by charge-reversal at arginine residue positions. J Biol Chem 2004; 279: 11976-83.
77. Satchell DP, Sheynis T, Kolusheva S, et al. Quantitative interactions between Cryptdin-4 amino terminal variants and membranes. Peptides 2003; 24: 1795-805.
78. Ma G, Cheng Q. Manipulating FRET with polymeric vesicles: development of a mix-and-detect type fluorescence sensor for bacterial toxin. Langmuir 2006; 22: 6743-5.
79. Powers JPS, Hancock REW. The relationship between peptide structure and antibacterial activity. Peptides 2003; 24: 1681-91.
80. Blondelle SE, Lohner K, Aguilar MI. Induced conformation and lipid binding properties of cytolytic and antimicrobial peptides: Determination and biological specificity. Biochim Biophys Acta 1999; 1462: 89-108.
81. Shai Y, Oren Z. Diastereoisomers of cytolysins, a novel class of potent antibacterial peptides. J Biol Chem 1996; 271: 7305-8.
82. Epand RM, Epand RF. Lipid domains in bacterial membranes and the action of antimicrobial agents. Biochim Biophys Acta 2009; 1788: 289-94.
83. Chen J, Falla TJ, Liu H, et al. Development of protegrins for the treatment and prevention of oral mucositis: structure-activity relationships of synthetic protegrin analogues. Biopolymers 2000; 55: 88-98.
84. Tang M, Hong M. Structure and mechanism of beta-hairpin antimicrobial peptides in lipid bilayers from solid-state NMR spectroscopy. Mol Biosyst 2009; 5: 317-22.
85. Robinson JA, Shankaramma SC, Jetter P, et al. Properties and structure-activity studies of cyclic beta-hairpin peptidomimetics based on the cationic antimicrobial peptide protegrin I. Bioorg Med Chem 2005; 13: 2055-64.
86. Fázio MA, Oliveira VX Jr, Bulet P, Miranda MT, Daffre S, Miranda A. Structure-activity relationship studies of gomesin: importance of the disulfide bridges for conformation, bioactivities, and serum stability. Biopolymers 2006; 84: 205-18.
87. Antcheva N, Morgera F, Creatti L, et al. Artificial beta-defensin based on a minimal defensin template. Biochem J 2009; 421: 435-47.
88. Pag U, Oedenkoven M, Sass V, et al. Analysis of in vitro activities and modes of action of synthetic antimicrobial peptides derived from an α-helical "sequence template". J Antimicrob Chemother 2008; 61: 341-52.
89. Shai Y. Mode of action of membrane active antimicrobial peptides. Biopolymers 2002; 66: 236-48.
90. Zou G, de Leeuw E, Li C, et al. Toward understanding the cationicity of defensins. Arg and Lys versus their noncoded analogs. J Biol Chem 2007; 282: 19653-65.
91. Matsuzaki K. Control of cell selectivity of antimicrobial peptides. Biochim Biophys Acta 2009; 1788: 1687-92.
92. Tachi T, Epand RF, Epand RM, Matsuzaki K. Position-dependent hydrophobicity of the antimicrobial magainin peptide affects the mode of peptide-lipid interactions and selective toxicity. Biochemistry 2002; 41: 10723-31.
93. Strøm MB, Haug BE, Rekdal O, Skar ML, Stensen W, Svendsen JS. Important structural features of 15-residue lactoferricin derivatives and methods for improvement of antimicrobial activity. Biochem Cell Biol 2002; 80: 65-74.
94. Perkins R, Fang H, Tong W, Welsh WJ. Quantitative structure activity relationship methods: perspectives on drug discovery and toxicology. Environ Toxicol Chem 2003; 22: 1666-79.
95. Hilpert K, Fjell CD, Cherkasov A. Short linear cationic antimicrobial peptides: screening, optimizing, and prediction. Methods Mol Biol 2008; 494: 127-59.
96. Bhonsle JB, Venugopal D, Huddler DP, Magill AJ, Hicks RP. Application of 3D-QSAR for identification of descriptors defining bioactivity of antimicrobial peptides. J Med Chem 2007; 50: 6545-53.
97. Taboureau O, Olsen OH, Nielsen JD, Raventos D, Mygind PH, Kristensen HH. Design of novispirin antimicrobial peptides by quantitative structure-activity relationship. Chem Biol Drug Des 2006; 68: 48-57.
98. Shu M, Jiang Y, Yang L, Wu Y, Mei H, Li Z. Application of 'HESH' descriptors for the structure-activity relationships of antimicrobial peptides. Protein Pept Lett 2009; 16: 143-9.
99. Juretić D, Vukicević D, Ilić N, Antcheva N, Tossi A. Computational design of highly selective antimicrobial peptides. J Chem Inf Model 2009; D49: 2873-82.
100. Cherkasov A. 'Inductive' descriptors. 10 successful years in QSAR. Curr Computer-Aided Drug Design 2005; 1: 21-42.
101. Fjell CD, Jenssen H, Hilpert K, et al. Identification of novel antibacterial peptides by chemoinformatics and machine learning. J Med Chem 2009; 52: 2006-15.
102. Zhou P, Chen X, Wu Y, Shang Z. Gaussian process: an alternative approach for QSAM modeling of peptides. Amino Acids 2010; 38: 199-212.
103. Vlieghe P, Lisowski V, Martinez J, Khrestchatisky M. Synthetic therapeutic peptides: science and market. Drug Discov Today 2010; 15: 40-56.
104. Antosova Z, Mackova M, Kral V, Macek T. Therapeutic application of peptides and proteins: parenteral forever? Trends Biotechnol 2009; 27: 628-35.
105. Diamond G, Beckloff N, Weinberg A, Kisich KO. The roles of antimicrobial peptides in innate host defense. Curr Pharm Des 2009; 15(21): 2377-92.
106. Hiemstra PS, Fernie-King BA, McMichael J, Lachmann PJ, Sallenave JM. Antimicrobial peptides: mediators of innate immunity as templates for the development of novel anti-infective and immune therapeutics. Curr Pharm Des 2004; 10(23): 2891-905.
107. Lee KH. Development of short antimicrobial peptides derived from host defense peptides or by combinatorial libraries. Curr Pharm Des 2002; 8(9): 795-13.